Spruce Biosciences SPRB

$ 0.49 -0.79%

Quarterly report 2024-Q3
added 11-12-2024

Spruce Biosciences Balance Sheet 2011-2024 | SPRB

Annual Balance Sheet Spruce Biosciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-94.4 M	-19.6 M	-37.5 M	-155 K	521 K	-4.11 M	-	-	-	-	-	-	-
Long Term Debt	1.72 M	3.29 M	4.88 M	-	3.19 M	-	-	-	-	-	-	-	-
Long Term Debt Current	251 K	1.62 M	360 K	249 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	31 M	19.9 M	-	-	-	-	-	-	-
Total Current Liabilities	24.5 M	12.4 M	8.87 M	9.76 M	-	-	-	-	-	-	-	-	-
Total Liabilities	27.4 M	17.2 M	15.1 M	13.5 K	35.3 M	22.6 M	-	-	-	-	-	-	-
Deferred Revenue	4.91 M	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-197 M	-149 M	-103 M	-	-31.3 M	-18.2 M	-	-	-	-	-	-	-
Total Assets	104 M	85.6 M	126 M	163 K	4.69 M	4.78 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	96.3 M	24.5 M	42.7 M	157 M	-	-	-	-	-	-	-	-	-
Book Value	76.5 M	68.5 M	111 M	149 K	-30.6 M	-17.8 M	-	-	-	-	-	-	-
Total Shareholders Equity	76.5 M	68.5 M	111 M	149 M	-30.6 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Spruce Biosciences

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	524 K	923 K	1.32 M	1.72 M	2.11 M	2.51 M	2.9 M	3.29 M	3.68 M	4.08 M	4.48 M	4.88 M	4.87 M	4.86 M	4.84 M	1.92 M	1.92 M	1.92 M	1.92 M	3.19 M	3.19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	13.5 M	16.4 M	20.9 M	27.4 M	27.6 M	29.4 M	31.1 M	17.2 M	16.8 M	15.4 M	14.7 M	15.1 M	15.4 M	13.3 M	13.3 M	13.5 M	13.5 M	13.5 M	13.5 M	7.52 M	7.52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	697 K	1.3 M	2.91 M	4.91 M	7.8 M	8.06 M	9.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-227 M	-218 M	-209 M	-197 M	-187 M	-175 M	-162 M	-149 M	-138 M	-127 M	-115 M	-103 M	-93.9 M	-82.5 M	-70.7 M	-60.8 M	-60.8 M	-60.8 M	-60.8 M	-31.3 M	-31.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	65.1 M	75.5 M	87.5 M	104 M	113 M	126 M	139 M	85.6 M	95.3 M	105 M	115 M	126 M	135 M	143 M	154 M	163 M	163 M	163 M	163 M	4.69 M	4.69 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	60.1 M	69.7 M	81.2 M	96.3 M	98.8 M	97.5 M	73.9 M	24.5 M	21.6 M	47.2 M	23.3 M	42.7 M	58.4 M	78.3 M	149 M	157 M	157 M	157 M	157 M	3.92 M	3.92 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	51.6 M	59.2 M	66.6 M	76.5 M	85.4 M	96.6 M	108 M	68.5 M	78.5 M	89.1 M	100 M	111 M	120 M	130 M	141 M	149 M	149 M	149 M	149 M	-2.82 M	-2.82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	51.6 M	59.2 M	66.6 M	76.5 M	85.4 M	96.6 M	108 M	68.5 M	78.5 M	89.1 M	100 M	111 M	120 M	130 M	141 M	149 M	149 M	149 M	149 M	-30.6 M	-30.6 M	-25.1 M	-21.9 M	-17.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency